[go: up one dir, main page]

PE20142083A1 - Derivados de anilina, su preparacion y su aplicacion terapeutica - Google Patents

Derivados de anilina, su preparacion y su aplicacion terapeutica

Info

Publication number
PE20142083A1
PE20142083A1 PE2014000357A PE2014000357A PE20142083A1 PE 20142083 A1 PE20142083 A1 PE 20142083A1 PE 2014000357 A PE2014000357 A PE 2014000357A PE 2014000357 A PE2014000357 A PE 2014000357A PE 20142083 A1 PE20142083 A1 PE 20142083A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
aniline
derivatives
preparation
Prior art date
Application number
PE2014000357A
Other languages
English (en)
Inventor
John Feutrill
Caroline Leriche
David Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20110306170 external-priority patent/EP2570402A1/en
Priority claimed from EP12305130.2A external-priority patent/EP2623490A1/en
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of PE20142083A1 publication Critical patent/PE20142083A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/68—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings containing halogen
    • C07C63/72—Polycyclic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL COMPUESTO DE FORMULA (I), DONDE R1a ES H, HALOGENO, ENTRE OTROS; R1b ES H, HALOGENO, ALQUILO (C1-C6), R1c ES H, ALQUILO (C1-C6); R2 ES H, HALOGENO, OH, ENTRE OTROS; R3 ES H, ALQUILO C1-C6, CONH2, ENTRE OTROS; R4 ES H, HALOGENO, UN ALQUILO C1-C6; R5, R7, R8 ES H, F; R9 ES H, ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS: ACIDO 2-[3-[[3-(3-FLUOROFENIL)-5-METIL-FENIL]METILAMINO]-2,4-DIMETIL-FENOXI]ACETICO; ACIDO 2-[3-[[5-(3-FLUOROFENIL)-2,3-DIMETIL-FENIL]METILAMINO]-2,4-DIMETIL-FENOXI]ACETICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL EN EL TRATAMIENTO DE GLAUCOMA.
PE2014000357A 2011-09-16 2012-09-07 Derivados de anilina, su preparacion y su aplicacion terapeutica PE20142083A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20110306170 EP2570402A1 (en) 2011-09-16 2011-09-16 Bi-aryl derivatives, their preparation and their therapeutic application
EP12305130.2A EP2623490A1 (en) 2012-02-03 2012-02-03 2-(3-aminophenoxy)-acetic acid derivatives as EP2 receptor agonists for use in treatment of glaucoma
EP12305626 2012-06-04

Publications (1)

Publication Number Publication Date
PE20142083A1 true PE20142083A1 (es) 2014-12-30

Family

ID=46889016

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000357A PE20142083A1 (es) 2011-09-16 2012-09-07 Derivados de anilina, su preparacion y su aplicacion terapeutica

Country Status (25)

Country Link
US (2) US9249085B2 (es)
EP (1) EP2755944B1 (es)
JP (2) JP2014530177A (es)
KR (1) KR20140097127A (es)
CN (1) CN103930396B (es)
AR (1) AR087814A1 (es)
AU (1) AU2012307527B2 (es)
BR (1) BR112014005935A2 (es)
CA (1) CA2848229C (es)
CL (1) CL2014000639A1 (es)
CO (1) CO6910193A2 (es)
DO (1) DOP2014000053A (es)
EA (1) EA026702B1 (es)
EC (1) ECSP14013249A (es)
GT (1) GT201400050A (es)
IL (1) IL231444A (es)
MA (1) MA35816B1 (es)
MX (1) MX347855B (es)
NI (1) NI201400021A (es)
PE (1) PE20142083A1 (es)
PH (1) PH12014500585B1 (es)
SG (1) SG11201400555SA (es)
UY (1) UY34314A (es)
WO (1) WO2013037705A2 (es)
ZA (1) ZA201401852B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2623490A1 (en) * 2012-02-03 2013-08-07 Fovea Pharmaceuticals 2-(3-aminophenoxy)-acetic acid derivatives as EP2 receptor agonists for use in treatment of glaucoma
PH12014500585B1 (en) 2011-09-16 2018-09-07 Sanofi Sa Aniline derivatives, their preparation and their therapeutic application
PT3083554T (pt) * 2013-12-17 2019-06-11 Lilly Co Eli Compostos de ácido dimetilbenzóico
WO2016001452A1 (en) 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
CN104530113A (zh) * 2014-12-22 2015-04-22 上海树农化工有限公司 邻氟苯甲酸类化合物及其制备方法
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
CN106905181B (zh) * 2017-04-14 2018-10-09 上海海洋大学 一种立达霉代谢产物16的合成方法
CN107162921B (zh) * 2017-05-27 2019-12-13 中国药科大学 一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
CN112920078A (zh) * 2019-12-05 2021-06-08 武汉珈汇精化科技有限公司 一种制备4-氰基苯甲酸甲酯的方法和一种制备4-氰基苯甲酸的方法
CN113651715B (zh) * 2021-09-13 2023-12-08 江苏弘和药物研发有限公司 一种一锅法合成香豆酰多巴胺的方法
CN113636949A (zh) * 2021-09-13 2021-11-12 江苏弘和药物研发有限公司 一种一锅法合成咖啡酰多巴胺的方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1920828A (en) * 1933-08-01 Amino-xylenois and process of
US1969354A (en) * 1932-08-06 1934-08-07 Squibb & Sons Inc 3-carboxy-4-alkoxy-diphenyl and salts thereof
US3671636A (en) * 1969-10-29 1972-06-20 Merck & Co Inc Methods for treating hypertension or inhibiting gastric secretion
US4564640A (en) * 1981-07-06 1986-01-14 William H. Rorer, Inc. Amidinoureas substituted in both the urea and amidino nitrogen positions
FR2673533B1 (fr) * 1991-03-05 1993-06-11 Oreal Procede de teinture des fibres keratiniques associant l'isatine ou ses derives a une aniline tri-, tetra- ou pentasubstituee, et agents de teinture.
DE4430757A1 (de) * 1994-08-30 1996-03-07 Boehringer Mannheim Gmbh Neue 4-Aminopyridazine, Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel
JPH08333287A (ja) 1995-06-02 1996-12-17 Fuji Yakuhin Kogyo Kk 芳香環置換アルキルカルボン酸及びアルカノール誘導体とそれらを含有する抗血栓剤
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6369271B1 (en) 1999-02-26 2002-04-09 Boehringer Ingelheim Pharma Kg Process for preparing derivatives of biphenyl-2-carboxylic acid
DE19962294A1 (de) 1999-12-23 2001-09-06 Metsae Tissue Oyj Espoo Tissue- und/oder tissueähnliches Material sowie Verfahren zu dessen Herstellung
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JPWO2004007439A1 (ja) 2002-07-10 2005-11-10 住友製薬株式会社 ビアリール誘導体
AU2003256923A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
US20060100245A1 (en) 2002-12-19 2006-05-11 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues
ATE492278T1 (de) 2003-07-23 2011-01-15 Synta Pharmaceuticals Corp Verbindungen gegen entzündungen und immun- relevante verwendungen
BRPI0414554A (pt) 2003-10-28 2006-11-07 Reddys Lab Ltd Dr compostos e seus usos em medicina: processo para preparação destes e composições farmacêuticas que os contenham
JP4745244B2 (ja) 2003-11-05 2011-08-10 エフ．ホフマン−ラ ロシュ アーゲー Ｐｐａｒアゴニストとしてのフェニル誘導体
JP2005179281A (ja) 2003-12-19 2005-07-07 Sumitomo Pharmaceut Co Ltd ビフェニル化合物
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
US7786165B2 (en) * 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
BRPI0511173A (pt) 2004-05-17 2007-12-04 Tibotec Pharm Ltd 1-fenil-1,5-diidro-pirido-(3,2b)indol-2-onas substituìdas nas posições 6,7,8,9, de utilidade como agentes farmacêuticos antiinfecciosos
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US7700628B2 (en) 2004-11-24 2010-04-20 Eli Lilly And Company Aromatic ether derivatives useful as thrombin inhibitors
WO2006083477A2 (en) 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007017687A2 (en) * 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
CA2621406A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
JP4825636B2 (ja) * 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規１，２−ジヒドロキノリン誘導体
US7910742B2 (en) * 2005-09-29 2011-03-22 Abbott Laboratories Survivin inhibitors
AR056691A1 (es) 2005-10-13 2007-10-17 Glaxo Group Ltd Derivados pirrolopirimidina como inhibidores de syk
KR101088942B1 (ko) 2006-07-28 2011-12-01 화이자 프로덕츠 인코포레이티드 Ｅｐ2 작용제
WO2008024634A1 (en) * 2006-08-25 2008-02-28 Smithkline Beecham Corporation Pyrimdine compounds useful as kinase inhibitors
CA2673586A1 (en) 2006-12-26 2008-07-24 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
CN105037347B (zh) 2007-02-01 2018-06-01 泰博特克药品有限公司 Hcv巨环抑制剂的多晶形
JP5735799B2 (ja) 2007-04-06 2015-06-17 ニューロクライン バイオサイエンシーズ，インコーポレイテッド ゴナドトロピン放出ホルモン受容体拮抗薬およびそれに関連する方法
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
JP5913805B2 (ja) * 2007-10-05 2016-04-27 アキュセラ， インコーポレイテッド 疾患治療用アルコキシ化合物
US20090163481A1 (en) 2007-12-13 2009-06-25 Murphy Brian J Ppar-delta ligands and methods of their use
CA2713547A1 (en) * 2008-02-05 2009-08-13 Asterand Uk Limited Biaryl amides
GB0802169D0 (en) 2008-02-06 2008-03-12 Ecmo Associates Ltd Extracorporeal membrane oxygenation
EP2310371B1 (fr) * 2008-05-26 2013-05-15 Genfit Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies
JP2010006707A (ja) * 2008-06-24 2010-01-14 Daiichi Sankyo Co Ltd チアゼピン誘導体を含有する医薬
US8349852B2 (en) * 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2010118078A1 (en) * 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US20120220577A1 (en) 2009-06-04 2012-08-30 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
CA2763717A1 (en) * 2009-06-10 2010-12-16 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
US9090584B2 (en) * 2010-01-26 2015-07-28 Allergan, Inc. Therapeutic agents for treatment of ocular hypertension
CN102781924A (zh) 2010-02-25 2012-11-14 首尔大学校产学协力财团 用作过氧化物酶体增殖剂激活受体的配体的硒唑衍生物、其制备方法及其化合物的用途
KR101141556B1 (ko) 2010-02-25 2012-05-03 서울대학교산학협력단 퍼록시솜 증식자 활성화 수용체 리간드 셀레나졸 유도체, 이의 제조방법 및 이들 화합물의 용도
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
WO2012003145A2 (en) 2010-07-02 2012-01-05 Allergan, Inc. Therapeutic agents for ocular hypertension
US8609658B2 (en) 2011-07-27 2013-12-17 Allergan, Inc. N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
PH12014500585B1 (en) 2011-09-16 2018-09-07 Sanofi Sa Aniline derivatives, their preparation and their therapeutic application
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
JP2013166750A (ja) 2012-01-18 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ビアリールアミド誘導体またはその薬理学的に許容される塩からなる医薬
MX2014010272A (es) 2012-02-28 2015-08-14 Piramal Entpr Ltd Derivados del acido fenil alcanoico como agonistas gpr.
IN2014DN08840A (es) 2012-04-03 2015-05-22 Mitsui Chemicals Agro Inc

Also Published As

Publication number Publication date
EP2755944B1 (en) 2017-06-14
IL231444A0 (en) 2014-04-30
IL231444A (en) 2017-05-29
EA201490642A1 (ru) 2014-07-30
WO2013037705A2 (en) 2013-03-21
US20160199330A1 (en) 2016-07-14
EA026702B1 (ru) 2017-05-31
MX347855B (es) 2017-05-16
US9624159B2 (en) 2017-04-18
KR20140097127A (ko) 2014-08-06
CO6910193A2 (es) 2014-03-31
CL2014000639A1 (es) 2014-11-03
UY34314A (es) 2013-04-30
WO2013037705A9 (en) 2013-09-06
JP2014530177A (ja) 2014-11-17
NZ622329A (en) 2015-05-29
ZA201401852B (en) 2015-09-30
DOP2014000053A (es) 2014-07-15
CN103930396B (zh) 2016-11-16
CA2848229C (en) 2019-08-27
BR112014005935A2 (pt) 2017-03-28
ECSP14013249A (es) 2014-04-30
AR087814A1 (es) 2014-04-16
WO2013037705A3 (en) 2013-06-06
CN103930396A (zh) 2014-07-16
GT201400050A (es) 2014-12-23
MX2014003206A (es) 2014-11-10
JP6272976B2 (ja) 2018-01-31
US20140350019A1 (en) 2014-11-27
AU2012307527B2 (en) 2017-07-20
CA2848229A1 (en) 2013-03-21
PH12014500585A1 (en) 2014-04-28
MA35816B1 (fr) 2014-12-01
EP2755944A2 (en) 2014-07-23
PH12014500585B1 (en) 2018-09-07
SG11201400555SA (en) 2014-04-28
JP2017052777A (ja) 2017-03-16
AU2012307527A1 (en) 2014-04-03
NI201400021A (es) 2014-04-23
US9249085B2 (en) 2016-02-02

Similar Documents

Publication Publication Date Title
PE20142083A1 (es) Derivados de anilina, su preparacion y su aplicacion terapeutica
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20130235A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
PE20140245A1 (es) Compuesto de furo[3,2-d]pirimidina
PE20140831A1 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
NZ716598A (en) Anthelmintic compounds and compositions and method of using thereof
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
PE20140011A1 (es) Compuestos y composiciones novedosos para la inhibicion de nampt
NZ716420A (en) Fused heterocyclic compounds as sodium channel modulators
PE20140966A1 (es) Quinazolincarboxamida azetidinas
EA201100503A1 (ru) Глюкозидные производные и их применения
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
UY32409A (es) Compuesto de anillo fusionado y su uso
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
PE20142282A1 (es) Nuevos derivados de aril-quinolina
AR077227A1 (es) Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
MX2013001234A (es) Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a.
PE20141201A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
MX2015014336A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.

Legal Events

Date Code Title Description
FC Refusal